Compare Biocon with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ASTRAZENECA PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ASTRAZENECA PHARMA BIOCON /
ASTRAZENECA PHARMA
 
P/E (TTM) x 31.5 126.0 25.0% View Chart
P/BV x 3.7 38.6 9.7% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    ASTRAZENECA PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
ASTRAZENECA PHARMA
Mar-18
BIOCON /
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs7071,278 55.3%   
Low Rs554883 62.7%   
Sales per share (Unadj.) Rs91.9228.4 40.2%  
Earnings per share (Unadj.) Rs16.710.4 161.2%  
Cash flow per share (Unadj.) Rs24.216.3 148.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.698.8 102.9%  
Shares outstanding (eoy) m600.0025.00 2,400.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.7 145.1%   
Avg P/E ratio x37.7104.2 36.2%  
P/CF ratio (eoy) x26.166.4 39.3%  
Price / Book Value ratio x6.210.9 56.7%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,33027,008 1,400.8%   
No. of employees `0006.11.4 452.1%   
Total wages/salary Rs m11,6531,535 759.0%   
Avg. sales/employee Rs Th8,994.34,210.9 213.6%   
Avg. wages/employee Rs Th1,900.71,132.2 167.9%   
Avg. net profit/employee Rs Th1,635.3191.1 855.8%   
INCOME DATA
Net Sales Rs m55,1445,710 965.7%  
Other income Rs m1,444123 1,178.8%   
Total revenues Rs m56,5885,833 970.2%   
Gross profit Rs m15,883463 3,431.2%  
Depreciation Rs m4,478147 3,038.0%   
Interest Rs m7090-   
Profit before tax Rs m12,140438 2,771.7%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123179 1,186.7%   
Profit after tax Rs m10,026259 3,869.5%  
Gross profit margin %28.88.1 355.3%  
Effective tax rate %17.540.8 42.8%   
Net profit margin %18.24.5 400.7%  
BALANCE SHEET DATA
Current assets Rs m48,2283,209 1,502.8%   
Current liabilities Rs m30,3762,070 1,467.8%   
Net working cap to sales %32.420.0 162.2%  
Current ratio x1.61.6 102.4%  
Inventory Days Days6872 94.4%  
Debtors Days Days8635 244.9%  
Net fixed assets Rs m64,130790 8,114.6%   
Share capital Rs m3,00050 6,000.0%   
"Free" reserves Rs m57,9802,419 2,396.6%   
Net worth Rs m60,9802,469 2,469.5%   
Long term debt Rs m15,7660-   
Total assets Rs m121,9244,605 2,647.4%  
Interest coverage x18.1NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 36.5%   
Return on assets %8.85.6 156.5%  
Return on equity %16.410.5 156.7%  
Return on capital %16.817.7 94.5%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,506300 5,176.4%   
Fx outflow Rs m10,3992,015 516.1%   
Net fx Rs m5,107-1,715 -297.7%   
CASH FLOW
From Operations Rs m11,54688 13,135.4%  
From Investments Rs m-7,138-94 7,626.1%  
From Financial Activity Rs m-2,417NA-  
Net Cashflow Rs m2,103-6 -36,894.7%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 15.7 68.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 12,856 855.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  TORRENT PHARMA  DISHMAN PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 7, 2021 (Close)

TRACK BIOCON

BIOCON - SUN PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS